Table 1 Baseline characteristics of the patients who received neoadjuvant SABR
Variables | Case No. | |||||||
|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | |
Gender | Male | Female | Male | Male | Male | Female | Male | Male |
Age | 60 | 61 | 63 | 50 | 46 | 60 | 76 | 34 |
BMI | 21.5 | 20.6 | 21.2 | 19.4 | 25.3 | 25.4 | 20.5 | 25.9 |
ECOG performance status | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
ASA classification | I | III | III | II | III | II | II | II |
Tumor side | Right | Left | Right | Right | Right | Left | Right | Right |
Tumor diameter/cm | 10.4 | 5.6 | 7.5 | 8.3 | 12 | 5.6 | 14.2 | 12.2 |
Clinical T stage | 3b | 3b | 4 | 4 | 3c | 4 | 4 | 3b |
Clinical N stage | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
Clinical M stage | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Mayo grade | II | III | III | II | III | II | III | II |
Tumor thrombus length/cm | 4.6 | 5.5 | 8.9 | 3.5 | 14.4 | 5.7 | 10.1 | 6.5 |
Vascular wall invasion | No | No | No | Yes | Yes | Yes | Yes | No |